Department of General and Visceral Surgery, General District Hospital Ludwigsburg, Ludwigsburg, Germany.
Colorectal Dis. 2011 Aug;13(8):855-9. doi: 10.1111/j.1463-1318.2010.02293.x. Epub 2010 Apr 28.
Sentinel lymph node mapping has been used in colon cancer to improve prognosis. This study aimed to determine the accuracy of in vivo SLNM in patients with colon carcinoma undergoing surgery with curative intent.
Thirty-one patients operated for colon carcinoma underwent in vivo sentinel lymph node mapping using patent blue dye. Each sentinel lymph node (SLN) was marked intraoperatively, and histological examination was performed after en bloc resection. If no metastasis was found, step sectioning with immunohistochemistry was performed.
The SLN was successfully identified in 28 (90%) of 31 patients. The false-negative rate to identify stage III disease was 66% (eight of 12), the negative predictive value was 46% (19 of 27) and the accuracy was 14% (four of 28). One patient negative on routine histopathology had micrometastasis on step sectioning of the SLN.
Sentinel lymph node mapping in colon carcinoma cannot accurately predict nodal status.
前哨淋巴结绘图已被用于结肠癌以改善预后。本研究旨在确定有治愈意图手术的结肠癌患者体内 SLNM 的准确性。
31 例行结肠癌手术的患者采用专利蓝染料进行体内前哨淋巴结绘图。每个前哨淋巴结 (SLN) 在术中进行标记，并在整块切除后进行组织学检查。如果未发现转移，则进行免疫组织化学的连续切片检查。
28 例（90%）31 例患者成功识别出 SLN。识别 III 期疾病的假阴性率为 66%（12 例中的 8 例），阴性预测值为 46%（27 例中的 19 例），准确性为 14%（28 例中的 4 例）。1 例常规组织病理学检查阴性的患者在前哨淋巴结的连续切片中有微转移。
结肠癌的前哨淋巴结绘图不能准确预测淋巴结状态。
